<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CSI-TME: Spatial Isoform Validation Report</title>
    <style>
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            line-height: 1.6;
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        .container {
            background-color: white;
            padding: 30px;
            border-radius: 10px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            margin-bottom: 20px;
        }
        h1 {
            color: #2c3e50;
            border-bottom: 3px solid #3498db;
            padding-bottom: 10px;
        }
        h2 {
            color: #34495e;
            border-left: 4px solid #3498db;
            padding-left: 15px;
            margin-top: 30px;
        }
        h3 {
            color: #7f8c8d;
        }
        .summary-box {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
        }
        .summary-box h3 {
            color: white;
            margin-top: 0;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        th, td {
            padding: 12px;
            text-align: left;
            border-bottom: 1px solid #ddd;
        }
        th {
            background-color: #3498db;
            color: white;
        }
        tr:hover {
            background-color: #f5f5f5;
        }
        .validated {
            color: #27ae60;
            font-weight: bold;
        }
        .not-validated {
            color: #e74c3c;
            font-weight: bold;
        }
        .figure-container {
            text-align: center;
            margin: 30px 0;
            padding: 20px;
            background-color: #f9f9f9;
            border-radius: 10px;
        }
        .figure-container img {
            max-width: 100%;
            height: auto;
            border-radius: 5px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        .figure-caption {
            font-style: italic;
            color: #666;
            margin-top: 10px;
        }
        .key-finding {
            background-color: #e8f6ff;
            border-left: 4px solid #3498db;
            padding: 15px;
            margin: 20px 0;
        }
        .warning {
            background-color: #fff3cd;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 20px 0;
        }
        code {
            background-color: #f4f4f4;
            padding: 2px 6px;
            border-radius: 3px;
            font-family: 'Courier New', monospace;
        }
        .stats {
            display: flex;
            justify-content: space-around;
            flex-wrap: wrap;
            margin: 20px 0;
        }
        .stat-box {
            text-align: center;
            padding: 20px;
            background-color: #f8f9fa;
            border-radius: 10px;
            min-width: 150px;
            margin: 10px;
        }
        .stat-number {
            font-size: 2.5em;
            font-weight: bold;
            color: #3498db;
        }
        .stat-label {
            color: #666;
            font-size: 0.9em;
        }
        .interpretation-box {
            background-color: #f0fff0;
            border: 1px solid #90EE90;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
        }
        .new-results {
            background-color: #e8f4fd;
            border: 2px solid #3498db;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
        }
        .new-results h3 {
            color: #2980b9;
            margin-top: 0;
        }
        .test-badge {
            display: inline-block;
            background-color: #9b59b6;
            color: white;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 0.85em;
            font-weight: bold;
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>CSI-TME: Spatial Isoform Validation Report</h1>
        <p><strong>Generated:</strong> February 4, 2026</p>
        <p><strong>Project:</strong> Cytokine & Secreted protein spatial Isoform distribution inference in the Tumor MicroEnvironment</p>

        <div class="summary-box">
            <h3>Executive Summary</h3>
            <p>This report presents spatial isoform analysis results from SPLISOSM on Visium ONT glioma data, with validation using an independent scRNA-seq dataset (32,304 cells). Using the <strong>HSIC-IR</strong> (Isoform Ratio) test, analysis of 26 SecAct target genes across 11 ONT samples identified 20 genes with significant spatial isoform variation. Two genes (APP, VCAN) were successfully validated in scRNA-seq.</p>
        </div>

        <div class="stats">
            <div class="stat-box">
                <div class="stat-number">20</div>
                <div class="stat-label">Significant Genes (HSIC-IR)</div>
            </div>
            <div class="stat-box">
                <div class="stat-number">11</div>
                <div class="stat-label">ONT Samples</div>
            </div>
            <div class="stat-box">
                <div class="stat-number">32,304</div>
                <div class="stat-label">Cells Validated</div>
            </div>
            <div class="stat-box">
                <div class="stat-number">5.1e-74</div>
                <div class="stat-label">Best p-value (HSIC-IR)</div>
            </div>
        </div>
    </div>

    <div class="container">
        <h2>1. Data Sources</h2>

        <h3>Discovery Dataset (Visium ONT)</h3>
        <table>
            <tr><th>Attribute</th><th>Value</th></tr>
            <tr><td>Source</td><td>Zenodo 16905935 (SPLISOSM paper)</td></tr>
            <tr><td>Platform</td><td>Visium + Oxford Nanopore (long-read)</td></tr>
            <tr><td>Samples</td><td>11 glioma samples (5 DMG, 6 GBM)</td></tr>
            <tr><td>Genes Tested</td><td>26 SecAct targets with 2+ isoforms</td></tr>
            <tr><td>Primary Test</td><td><span class="test-badge">HSIC-IR</span> (Isoform Ratio spatial variation)</td></tr>
        </table>

        <h3>Validation Dataset (scRNA-seq)</h3>
        <table>
            <tr><th>Attribute</th><th>Value</th></tr>
            <tr><td>Source</td><td>Zenodo 17055113</td></tr>
            <tr><td>Publication</td><td>"Single-Cell Atlas of RNA Alternative Splicing in the Glioma-Immune Ecosystem"</td></tr>
            <tr><td>Platform</td><td>SMART-seq2</td></tr>
            <tr><td>Cells</td><td>32,304 total (17,918 tumor, 7,064 T cells, 4,312 macrophages)</td></tr>
            <tr><td>Splicing Tool</td><td>MARVEL (PSI quantification)</td></tr>
        </table>

        <h3>SPLISOSM Test Statistics</h3>
        <table>
            <tr><th>Test</th><th>Abbreviation</th><th>Detects</th><th>Use Case</th></tr>
            <tr><td><strong>HSIC-IR</strong></td><td>Isoform Ratio</td><td>Spatial isoform switching independent of expression</td><td><strong>Primary test for this analysis</strong></td></tr>
            <tr><td>HSIC-GC</td><td>Gene Counts</td><td>Spatially variable gene expression</td><td>SVG detection</td></tr>
            <tr><td>HSIC-IC</td><td>Isoform Counts</td><td>Combined expression + composition</td><td>Initial screening</td></tr>
        </table>
    </div>

    <div class="container">
        <h2>2. ONT SPLISOSM Results Summary</h2>

        <div class="new-results">
            <h3>Top Spatially Variable Genes - <span class="test-badge">HSIC-IR</span> Test</h3>
            <p>Analysis of 26 SecAct target genes across 11 Visium ONT samples. Significance determined by <strong>HSIC-IR p-value < 0.05</strong>:</p>
            <table>
                <tr><th>Gene</th><th>Reproducibility</th><th>Best HSIC-IR p-value</th><th>Best Sample</th><th>Function</th></tr>
                <tr><td><strong>B2M</strong></td><td>11/11 (100%)</td><td>1.7e-67</td><td>GBM_1</td><td>MHC-I component</td></tr>
                <tr><td><strong>CLU</strong></td><td>11/11 (100%)</td><td>5.1e-74</td><td>GBM_1</td><td>Stress response chaperone</td></tr>
                <tr><td><strong>MIF</strong></td><td>9/11 (82%)</td><td>2.2e-21</td><td>GBM_3</td><td>Macrophage migration factor</td></tr>
                <tr><td><strong>CD74</strong></td><td>8/11 (73%)</td><td>5.5e-38</td><td>GBM_1</td><td>MHC-II invariant chain</td></tr>
                <tr><td><strong>PTGDS</strong></td><td>6/11 (55%)</td><td>8.2e-63</td><td>GBM_1</td><td>Prostaglandin synthase</td></tr>
                <tr><td><strong>TIMP1</strong></td><td>6/11 (55%)</td><td>3.3e-16</td><td>DMG_1</td><td>MMP inhibitor</td></tr>
                <tr><td><strong>LGALS1</strong></td><td>6/11 (55%)</td><td>4.1e-16</td><td>DMG_3</td><td>Galectin-1 (immune)</td></tr>
                <tr><td><strong>ITM2B</strong></td><td>6/11 (55%)</td><td>3.9e-12</td><td>GBM_3</td><td>Membrane protein</td></tr>
                <tr><td><strong>CST3</strong></td><td>6/11 (55%)</td><td>2.4e-24</td><td>DMG_3</td><td>Cystatin C</td></tr>
                <tr><td><strong>SPARCL1</strong></td><td>4/11 (36%)</td><td>2.3e-20</td><td>DMG_2</td><td>ECM protein</td></tr>
            </table>
        </div>
    </div>

    <div class="container">
        <h2>3. APP (Amyloid Precursor Protein) Validation</h2>

        <div class="key-finding">
            <strong>Key Finding:</strong> APP exon 7/8 inclusion shows dramatic differences between tumor states, with mesenchymal-like cells showing high inclusion (82%) and neural progenitor-like cells showing low inclusion (27%). Spatial variation detected by <span class="test-badge">HSIC-IR</span>.
        </div>

        <h3>Visium SR Results - <span class="test-badge">HSIC-IR</span></h3>
        <table>
            <tr><th>Sample</th><th>Isoforms</th><th>HSIC-IR p-value</th><th>Significant (IR)</th></tr>
            <tr><td>ZH916bulk</td><td>3</td><td>5.72e-28</td><td class="validated">YES</td></tr>
            <tr><td>ZH881T1</td><td>2</td><td>4.51e-12</td><td class="validated">YES</td></tr>
            <tr><td>ZH1007inf</td><td>3</td><td>1.55e-05</td><td class="validated">YES</td></tr>
            <tr><td>ZH1007nec</td><td>3</td><td>4.98e-03</td><td class="validated">YES</td></tr>
            <tr><td>ZH916inf</td><td>5</td><td>1.10e-01</td><td class="not-validated">no</td></tr>
            <tr><td>MGH258</td><td>2</td><td>3.05e-01</td><td class="not-validated">no</td></tr>
            <tr><td>ZH881inf</td><td>2</td><td>2.49e-01</td><td class="not-validated">no</td></tr>
        </table>

        <h3>scRNA-seq Validation</h3>
        <table>
            <tr><th>Tumor State</th><th>n cells</th><th>Mean PSI</th><th>SD</th></tr>
            <tr><td>Tumor_MES (mesenchymal)</td><td>538</td><td>82.2%</td><td>28.6</td></tr>
            <tr><td>Tumor_AC (astrocyte-like)</td><td>459</td><td>74.9%</td><td>32.6</td></tr>
            <tr><td>Tumor_Cycling</td><td>199</td><td>62.3%</td><td>38.6</td></tr>
            <tr><td>Tumor_OPC_N (OPC neural)</td><td>1105</td><td>53.6%</td><td>39.0</td></tr>
            <tr><td>Tumor_OPC_OL (OPC oligo)</td><td>187</td><td>52.1%</td><td>42.7</td></tr>
            <tr><td style="background-color:#ffe6e6">Tumor_NPC (neural progenitor)</td><td>200</td><td style="background-color:#ffe6e6"><strong>27.0%</strong></td><td>36.9</td></tr>
        </table>

        <p><strong>Statistical Test:</strong> Tumor_MES vs Tumor_NPC: ΔPSI = 55.2%, p = 8.57e-52 (Wilcoxon)</p>

        <div class="figure-container">
            <img src="fig1_app_psi_by_tumor_state.png" alt="APP PSI by Tumor State">
            <div class="figure-caption">Figure 1: APP exon 7/8 inclusion (PSI) varies dramatically between tumor cell states in scRNA-seq validation. Mesenchymal (MES) cells show high inclusion (82%), while neural progenitor-like (NPC) cells show low inclusion (27%). This cell-state-dependent splicing underlies the spatial patterns detected by HSIC-IR in Visium.</div>
        </div>

        <div class="interpretation-box">
            <h3>Biological Interpretation</h3>
            <p><strong>APP isoforms:</strong></p>
            <ul>
                <li><strong>APP695</strong> (exons 7/8 skipped) - Neural-specific, lacks KPI domain</li>
                <li><strong>APP751/770</strong> (exons 7/8 included) - Non-neural, contains KPI (Kunitz Protease Inhibitor) domain</li>
            </ul>
            <p><strong>Spatial implication:</strong> Regions enriched for neural progenitor-like tumor cells (NPC state) will have lower APP exon inclusion, while mesenchymal-rich regions will have higher inclusion. This creates detectable spatial isoform gradients detected by HSIC-IR.</p>
        </div>
    </div>

    <div class="container">
        <h2>4. VCAN (Versican) Validation</h2>

        <div class="key-finding">
            <strong>Key Finding:</strong> VCAN GAG-domain exon inclusion differs by 64% between mesenchymal (14%) and OPC-lineage (78%) tumor states. Spatial variation detected by <span class="test-badge">HSIC-IR</span>.
        </div>

        <h3>Visium SR Results - <span class="test-badge">HSIC-IR</span></h3>
        <table>
            <tr><th>Sample</th><th>Isoforms</th><th>HSIC-IR p-value</th><th>Significant (IR)</th></tr>
            <tr><td>ZH1019T1</td><td>7</td><td>3.65e-19</td><td class="validated">YES</td></tr>
            <tr><td>ZH1019inf</td><td>10</td><td>4.58e-12</td><td class="validated">YES</td></tr>
            <tr><td>ZH1007inf</td><td>8</td><td>5.81e-04</td><td class="validated">YES</td></tr>
            <tr><td>ZH1007nec</td><td>7</td><td>2.99e-04</td><td class="validated">YES</td></tr>
            <tr><td>ZH8811Abulk</td><td>3</td><td>4.01e-02</td><td class="validated">YES</td></tr>
            <tr><td>ZH881T1</td><td>4</td><td>2.09e-02</td><td class="validated">YES</td></tr>
            <tr><td>ZH916T1</td><td>3</td><td>4.39e-02</td><td class="validated">YES</td></tr>
            <tr><td>ZH916bulk</td><td>4</td><td>2.64e-02</td><td class="validated">YES</td></tr>
        </table>

        <h3>scRNA-seq Validation</h3>
        <table>
            <tr><th>Tumor State</th><th>n cells</th><th>Mean PSI</th><th>SD</th></tr>
            <tr><td style="background-color:#ffe6e6">Tumor_MES (mesenchymal)</td><td>78</td><td style="background-color:#ffe6e6"><strong>14.1%</strong></td><td>35.0</td></tr>
            <tr><td>Tumor_Cycling</td><td>22</td><td>18.6%</td><td>39.3</td></tr>
            <tr><td>Tumor_OPC_N (OPC neural)</td><td>55</td><td>60.6%</td><td>47.9</td></tr>
            <tr><td>Tumor_OPC_OL (OPC oligo)</td><td>37</td><td>78.2%</td><td>41.7</td></tr>
            <tr><td>Tumor_AC (astrocyte-like)</td><td>15</td><td>80.0%</td><td>41.4</td></tr>
            <tr><td>Tumor_NPC</td><td>12</td><td>0.0%</td><td>0.0</td></tr>
        </table>

        <p><strong>Statistical Test:</strong> Tumor_MES vs Tumor_OPC_OL: ΔPSI = 64.1%, p = 2.51e-11 (Wilcoxon)</p>

        <div class="figure-container">
            <img src="fig2_vcan_psi_by_tumor_state.png" alt="VCAN PSI by Tumor State">
            <div class="figure-caption">Figure 2: VCAN GAG-domain exon inclusion (PSI) varies between tumor cell states in scRNA-seq validation. OPC-lineage cells (OPC_OL: 78%, AC: 80%) show high inclusion, while mesenchymal cells show low inclusion (14%). This cell-state-dependent splicing underlies the spatial patterns detected by HSIC-IR in Visium.</div>
        </div>

        <div class="interpretation-box">
            <h3>Biological Interpretation</h3>
            <p><strong>VCAN isoforms (V0/V1/V2/V3):</strong></p>
            <ul>
                <li><strong>V0</strong> - Both GAG exons (7 and 8) included</li>
                <li><strong>V1</strong> - Exon 7 only (GAGα domain)</li>
                <li><strong>V2</strong> - Exon 8 only (GAGβ domain)</li>
                <li><strong>V3</strong> - Neither exon (no GAG domains)</li>
            </ul>
            <p><strong>Pattern:</strong> OPC-lineage cells prefer V0/V1-like forms (high exon inclusion), while mesenchymal cells prefer V2/V3-like forms (low inclusion). This reflects the different extracellular matrix requirements of these cell states.</p>
        </div>
    </div>

    <div class="container">
        <h2>5. CLU (Clusterin) Analysis</h2>

        <div class="key-finding">
            <strong>Key Finding:</strong> CLU shows the strongest and most reproducible spatial isoform variation by <span class="test-badge">HSIC-IR</span>, significant in ALL 11 samples (100%). However, scRNA-seq validation is inconclusive due to low splicing variability in SMART-seq2 data, possibly because novel ONT-detected isoforms are not captured.
        </div>

        <h3>Visium ONT Results - <span class="test-badge">HSIC-IR</span></h3>
        <table>
            <tr><th>Sample</th><th>Type</th><th>Isoforms</th><th>Spots</th><th>HSIC-IR p-value</th><th>Significant (IR)</th></tr>
            <tr><td>GBM_1</td><td>GBM</td><td>7</td><td>4345</td><td>5.13e-74</td><td class="validated">YES</td></tr>
            <tr><td>DMG_2</td><td>DMG</td><td>10</td><td>1038</td><td>7.53e-58</td><td class="validated">YES</td></tr>
            <tr><td>DMG_1</td><td>DMG</td><td>8</td><td>3704</td><td>1.60e-40</td><td class="validated">YES</td></tr>
            <tr><td>GBM_2</td><td>GBM</td><td>8</td><td>2729</td><td>3.33e-16</td><td class="validated">YES</td></tr>
            <tr><td>GBM_4</td><td>GBM</td><td>8</td><td>2361</td><td>1.60e-11</td><td class="validated">YES</td></tr>
            <tr><td>DMG_5</td><td>DMG</td><td>8</td><td>1003</td><td>2.08e-10</td><td class="validated">YES</td></tr>
            <tr><td>GBM_5</td><td>GBM</td><td>8</td><td>1983</td><td>1.52e-07</td><td class="validated">YES</td></tr>
            <tr><td>DMG_3</td><td>DMG</td><td>8</td><td>1816</td><td>8.83e-07</td><td class="validated">YES</td></tr>
            <tr><td>GBM_3</td><td>GBM</td><td>8</td><td>1667</td><td>1.63e-06</td><td class="validated">YES</td></tr>
            <tr><td>DMG_4</td><td>DMG</td><td>7</td><td>1947</td><td>5.43e-05</td><td class="validated">YES</td></tr>
            <tr><td>GBM_6</td><td>GBM</td><td>8</td><td>1510</td><td>1.56e-02</td><td class="validated">YES</td></tr>
        </table>

        <div class="figure-container">
            <img src="fig3_clu_visium_hsic_ir.png" alt="CLU HSIC-IR Significance">
            <div class="figure-caption">Figure 3: CLU spatial isoform variation significance (-log10 p-value) across all 11 ONT samples using the HSIC-IR test. All samples show significant spatial variation (p < 0.05). Red bars = GBM samples, Blue bars = DMG samples.</div>
        </div>

        <h3>ONT Isoform Discovery</h3>
        <p>CLU shows 7-10 isoforms per sample, including both known (CLU-201, CLU-208, CLU-215) and novel (CLU_Iso_1-5) isoforms:</p>
        <table>
            <tr><th>Isoform</th><th>Type</th><th>Tumor Regions</th><th>Immune Infiltration</th><th>Change</th></tr>
            <tr><td>CLU-201 (canonical secreted)</td><td>Known</td><td>14.1%</td><td>11.5%</td><td style="color:red">↓18%</td></tr>
            <tr><td>CLU-208</td><td>Known</td><td>26.9%</td><td>27.6%</td><td>↑3%</td></tr>
            <tr><td>CLU_Iso_1 (truncated)</td><td>Novel</td><td>20.8%</td><td>22.3%</td><td style="color:green">↑7%</td></tr>
            <tr><td>CLU_Iso_2 (truncated)</td><td>Novel</td><td>11.9%</td><td>12.5%</td><td style="color:green">↑5%</td></tr>
            <tr><td>CLU_Iso_3 (truncated)</td><td>Novel</td><td>16.6%</td><td>18.1%</td><td style="color:green">↑9%</td></tr>
        </table>

        <div class="warning">
            <strong>Validation Status:</strong> CLU could not be validated in scRNA-seq due to low splicing variability (max SD = 0.18). This is likely because the novel truncated isoforms detected by ONT long-read sequencing are not captured by SMART-seq2 3'-biased methods.
        </div>

        <div class="interpretation-box">
            <h3>Biological Interpretation</h3>
            <p><strong>CLU-201 (canonical):</strong> Contains signal peptide → secreted → cytoprotective/anti-apoptotic</p>
            <p><strong>CLU_Iso_1-5 (novel):</strong> 5'-truncated, likely lacking signal peptide → cytoplasmic/nuclear → potentially pro-apoptotic</p>
            <p><strong>Pattern:</strong> Tumor cores preferentially express the cytoprotective secreted form (CLU-201), while immune-infiltrated regions shift toward truncated forms. This may reflect stress response or cell type composition differences.</p>
        </div>
    </div>

    <div class="container">
        <h2>6. Additional Significant Genes - <span class="test-badge">HSIC-IR</span></h2>

        <p>Beyond APP, VCAN, and CLU, several other SecAct targets show strong spatial isoform variation by HSIC-IR:</p>

        <h3>Immune-Related Genes</h3>
        <table>
            <tr><th>Gene</th><th>Samples Sig (HSIC-IR)</th><th>Best HSIC-IR p-value</th><th>Isoforms</th><th>Function</th></tr>
            <tr><td><strong>B2M</strong></td><td>11/11</td><td>1.7e-67</td><td>4-6</td><td>Beta-2-microglobulin, MHC-I presentation</td></tr>
            <tr><td><strong>CD74</strong></td><td>8/11</td><td>5.5e-38</td><td>4-13</td><td>MHC-II invariant chain, antigen processing</td></tr>
            <tr><td><strong>MIF</strong></td><td>9/11</td><td>2.2e-21</td><td>2-4</td><td>Macrophage migration inhibitory factor</td></tr>
            <tr><td><strong>LGALS1</strong></td><td>6/11</td><td>4.1e-16</td><td>3-5</td><td>Galectin-1, immunosuppression</td></tr>
        </table>

        <h3>ECM/Stress Response Genes</h3>
        <table>
            <tr><th>Gene</th><th>Samples Sig (HSIC-IR)</th><th>Best HSIC-IR p-value</th><th>Isoforms</th><th>Function</th></tr>
            <tr><td><strong>TIMP1</strong></td><td>6/11</td><td>3.3e-16</td><td>2-6</td><td>Tissue inhibitor of metalloproteinases</td></tr>
            <tr><td><strong>SPARCL1</strong></td><td>4/11</td><td>2.3e-20</td><td>3-10</td><td>ECM glycoprotein</td></tr>
            <tr><td><strong>CST3</strong></td><td>6/11</td><td>2.4e-24</td><td>2</td><td>Cystatin C, protease inhibitor</td></tr>
            <tr><td><strong>PTGDS</strong></td><td>6/11</td><td>8.2e-63</td><td>2-7</td><td>Prostaglandin D2 synthase</td></tr>
        </table>
    </div>

    <div class="container">
        <h2>7. Validation Summary</h2>

        <table>
            <tr>
                <th>Gene</th>
                <th>Visium (HSIC-IR)</th>
                <th>scRNA-seq</th>
                <th>Concordance</th>
                <th>Status</th>
            </tr>
            <tr>
                <td><strong>APP</strong></td>
                <td>4/7 samples significant</td>
                <td>ΔPSI=55%, p<1e-50</td>
                <td>MES vs NPC states</td>
                <td class="validated">VALIDATED</td>
            </tr>
            <tr>
                <td><strong>VCAN</strong></td>
                <td>8/13 samples significant</td>
                <td>ΔPSI=64%, p<1e-10</td>
                <td>MES vs OPC states</td>
                <td class="validated">VALIDATED</td>
            </tr>
            <tr>
                <td><strong>CLU</strong></td>
                <td>11/11 samples significant</td>
                <td>Low variability (SD=0.18)</td>
                <td>Novel isoforms not in scRNA-seq</td>
                <td style="color:#f39c12"><strong>INCONCLUSIVE</strong></td>
            </tr>
            <tr>
                <td><strong>B2M</strong></td>
                <td>11/11 samples significant</td>
                <td>Not tested</td>
                <td>-</td>
                <td style="color:#3498db"><strong>PENDING</strong></td>
            </tr>
            <tr>
                <td><strong>CD74</strong></td>
                <td>8/11 samples significant</td>
                <td>Not tested</td>
                <td>-</td>
                <td style="color:#3498db"><strong>PENDING</strong></td>
            </tr>
        </table>

        <h3>Key Conclusions</h3>
        <ol>
            <li><strong>HSIC-IR detects true isoform switching</strong> - independent of expression changes, identifying genes with spatial splicing variation.</li>
            <li><strong>APP and VCAN isoform variation is cell-state-dependent</strong> - different tumor states have distinct splicing programs that create spatial gradients in tissue.</li>
            <li><strong>CLU and B2M show universal spatial variation</strong> - significant by HSIC-IR in all 11 samples, suggesting fundamental spatial regulation in glioma TME.</li>
            <li><strong>Immune-related genes prominent</strong> - B2M, CD74, MIF, LGALS1 all show strong HSIC-IR patterns, suggesting spatial immune niche regulation.</li>
            <li><strong>Novel isoforms detected by ONT</strong> (e.g., CLU truncated forms) may require alternative validation strategies beyond SMART-seq2.</li>
        </ol>
    </div>

    <div class="container">
        <h2>8. Methods Summary</h2>

        <h3>Visium ONT Analysis (Discovery)</h3>
        <ul>
            <li><strong>Tool:</strong> SPLISOSM (Spatial Isoform Statistical Omnibus Model)</li>
            <li><strong>Primary Statistic:</strong> <span class="test-badge">HSIC-IR</span> (Hilbert-Schmidt Independence Criterion for Isoform Ratio)</li>
            <li><strong>Kernel:</strong> Full-rank ICAR spatial kernel (k=15 neighbors, ρ=0.99)</li>
            <li><strong>P-value:</strong> Liu's chi-squared moment matching</li>
            <li><strong>Targets:</strong> 26 SecAct genes with 2+ isoforms detected</li>
            <li><strong>Significance threshold:</strong> HSIC-IR p-value < 0.05</li>
        </ul>

        <h3>scRNA-seq Analysis (Validation)</h3>
        <ul>
            <li><strong>Tool:</strong> MARVEL (single-cell splicing)</li>
            <li><strong>Metric:</strong> PSI (Percent Spliced In)</li>
            <li><strong>Events:</strong> SE, MXE, A5SS, A3SS, AFE, ALE</li>
            <li><strong>Statistical test:</strong> Wilcoxon rank-sum between tumor states</li>
        </ul>
    </div>

    <div class="container">
        <h2>9. Data Availability</h2>
        <table>
            <tr><th>Dataset</th><th>Location</th></tr>
            <tr><td>Visium ONT data</td><td><code>data/zenodo_16905935/human_glioma_ont/</code></td></tr>
            <tr><td>ONT SPLISOSM results</td><td><code>data/zenodo_16905935/human_glioma_ont/ont_secact_splisosm_results.csv</code></td></tr>
            <tr><td>scRNA-seq data</td><td><code>data/zenodo_17055113/</code></td></tr>
            <tr><td>Validation results</td><td><code>data/validation_results/</code></td></tr>
            <tr><td>Figures</td><td><code>reports/</code></td></tr>
        </table>
    </div>
</body>
</html>
